Armistice Capital LLC Makes New $5.26 Million Investment in PDS Biotechnology Corporation $PDSB

Key Points

• Armistice Capital LLC acquired 4,419,000 shares of PDS Biotechnology Corporation, representing approximately 9.68% of the company, valued at about $5.26 million.
• Several institutional investors have recently increased their holdings in PDS Biotechnology, contributing to 26.84% of the stock being owned by institutional investors and hedge funds.
• Analysts have mixed views on the stock, with Wall Street Zen downgrading it to a "sell" rating while HC Wainwright maintains a "buy" rating with a target price of $13.00.

Armistice Capital LLC bought a new position in shares of PDS Biotechnology Corporation (NASDAQ:PDSB - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 4,419,000 shares of the company's stock, valued at approximately $5,259,000. Armistice Capital LLC owned approximately 9.68% of PDS Biotechnology at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in PDS Biotechnology during the 4th quarter worth about $26,000. Jane Street Group LLC bought a new position in shares of PDS Biotechnology in the 4th quarter valued at about $58,000. Marshall Wace LLP grew its holdings in shares of PDS Biotechnology by 38.4% in the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company's stock valued at $64,000 after acquiring an additional 10,837 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of PDS Biotechnology by 273.5% in the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock valued at $107,000 after acquiring an additional 48,132 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of PDS Biotechnology by 331.0% in the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company's stock valued at $163,000 after acquiring an additional 76,800 shares in the last quarter. Institutional investors own 26.84% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PDSB. HC Wainwright restated a "buy" rating and issued a $13.00 price objective on shares of PDS Biotechnology in a report on Tuesday, July 1st. Wall Street Zen cut PDS Biotechnology from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $10.00.

PDS Biotechnology Stock Up 4.0%

PDSB traded up $0.05 during trading on Wednesday, hitting $1.30. The stock had a trading volume of 552,549 shares, compared to its average volume of 534,427. The company has a 50 day moving average price of $1.22 and a 200-day moving average price of $1.29. PDS Biotechnology Corporation has a one year low of $0.85 and a one year high of $4.29. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.92 and a current ratio of 2.92.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03. On average, equities research analysts anticipate that PDS Biotechnology Corporation will post -1.2 earnings per share for the current year.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.